



January 17, 2024

Re : Updated safety information regarding PROPECIA[®] (finasteride) - DIN 02238213

As of November 24, 2023, the Product Monograph of Organon's product, PROPECIA[®] (finasteride) has been updated to reflect safety concerns related to finasteride-containing products and suicide, suicidal ideation, and self-injury related events further to Health Canada's published Summary Safety Review for finasteride.

PROPECIA[®] is indicated for:

- the treatment of male pattern hair loss (androgenetic alopecia) in men who have mild to moderate scalp hair loss of the vertex and anterior mid-scalp.

For the complete prescribing information and information available for the patients/caregivers please consult the [PROPECIA[®] Product Monograph](#). The Product Monograph can be found on the [Organon Website](#), or by contacting Organon Canada at 1-844-820-5468.

Healthcare Professionals who have medical enquiries regarding PROPECIA[®] can contact our Medical Information Department at 1-844-820-5468, or via email at medinfocanada@organon.com.

For questions or concerns, patients are encouraged to contact their healthcare professional.

® N.V. Organon. Used under license.

© 2024 Organon group of companies. All rights reserved.